R&D Center of NovaMedica has received GMP-Certificate from the Ministry of Industry and Trade of the Russian Federation

26 December 2017

Moscow, December 26, 2017 – Russian pharmaceutical company NovaMedica, investment project of Rusnano, informed about receipt of conclusion of the Ministry of Industry and Trade of the Russian Federation over compliance of the facility of the R&D Center of NovaMedica Innotech (subsidiary of NovaMedica) with the Russian standards of the Good Manufacturing Practice (GMP). The certificate issued basing on the integrated audit of the MIT RF commission, proves that the processes of development, manufacturing and quality control at NovaMedica Innotech are organized in accordance with the high standards of quality and manufacturing of tablets, soft and hard gelatin capsules and pellets at its manufacturing facilities meet the Russian GMP requirements. 

«Now R&D Center will be able to provide partners with rather rare in the Russian pharmaceutical market set of services that includes development and manufacturing of complex drug products including with usage of exclusive for our market technologies such as hot extrusion, spheronization of granules, covering of pellets in a liquid bed. I am sure that positive conclusion from the experts regarding compliance of the manufacturing facility of NovaMedica Innotech with the GMP requirements will serve as an additional reason for our partners in making decision over selection of a CMO site for development and manufacturing in Russia”, noted Alexander Kuzin, CEO of NovaMedica.

Further plans of the R&D Center of NovaMedica include receipt of the international GMP certificate.

About NovaMedica

NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects

NovaMedica became key partner of Pfizer in Russia in 2016. Within this partnership NovaMedica started construction of the pharmaceutical GMP manufacturing facility in the Kaluga region in May 2017. In December 2017 Interdepartmental Commission approved NovaMedica’s application for SPIC to create new pharmaceutical manufacturing facility in the Kaluga region.

In April 2017 NovaMedica opened the Technological Center with state-of-the-art technological capabilities which were previously unavailable in the Russian pharmaceutical industry. In Q4 2017 R&D Center of NovaMedica received manufacturing license and the Russian GMP certificate from the Ministry of Industry and Trade of the Russian Federation.

NovaMedica possesses a well-developed infrastructure for promotion and sale of pharmaceutical products. Currently company is promoting a portfolio of 25 ophthalmological and gastroenterological products in the Russian market.  

More information here, follow us on Facebook and LinkedIn.

Previous publication Next publication

Media Center

  • 20 March 2018

    Russia establishes its National Quality Infrastructure Council

    On March 14, Denis Manturov, the Russian Minister of Industry and Trade, chaired a meeting of the State Commission on Counteraction to Illegal Circulation of Industrial Products. The Minister said that, ensuring the “market purity” would require, in addition to providing more preferences for entrepreneurs operating strictly within the legal field, to guarantee to potential consumers that they purchase genuine rather than counterfeit and falsified products.

  • 20 March 2018

    Researchers in aging tie genes to brain degeneration

    As brain cells age, they lose their ability to perform basic functions, often leading to dementia and other neurodegenerative disorders. But what’s behind this decline, and can it be stopped? Two new studies out this week uncover links between genes and brain-cell functioning that could provide new targets for therapies aimed at neurodegenerative diseases.

  • 19 March 2018

    China established a new drug regulator

    After about five years as a standalone agency, the China Food and Drug Administration (CFDA) will merge into a gigantic national market supervision administration, with drug regulation as a new, second-tier bureau underneath.

  • 19 March 2018

    Project of EAEU unified goods traceability system was presented to the public

    The unified goods traceability system in the Eurasian Economic Union (EAEU) will provide consumers with access to reliable information about products, allow businesses to reduce their transaction costs, let member states to monitor the payment of taxes, minimize smuggling, and protect consumers.

Read more